A higher percentage of patients with HER2 amplification, compared with those without HER2 amplification, were female (67% v 38%, P < .001) and had gallbladder cancer (58% v 29%, P < .001), with no significant differences in other characteristics between the two groups. This evidence concerns the gene ERBB2 and gallbladder cancer.